Bausch + Lomb: Positive Outcomes for Premium LuxSmart™ Intraocular Lenses, Following One-Year Real-World ExperienceBusiness Wire • 10/07/21
Bausch Health Companies Inc. Will Release Third-Quarter 2021 Financial Results On November 2PRNewsWire • 10/06/21
Bausch + Lomb Announces Statistically Significant Topline Results from the Second Phase 3 Trial Of NOV03 (perfluorohexyloctane) in Dry Eye Disease Associated with Meibomian Gland DysfunctionPRNewsWire • 09/30/21
Bausch Health Companies, Inc. (BHC) CEO Joseph Papa on Morgan Stanley 19th Annual Global Healthcare Conference (Transcript)Seeking Alpha • 09/13/21
Bausch Health files confidentially for IPOs of eye care business and medical aesthetics businessMarket Watch • 09/13/21
Bausch Health Companies, Inc. (BHC) CEO Joseph Papa on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/03/21
Bausch Health Misses On Q2 Sales, Cuts FY21 Outlook, Plans IPO For Medical Aesthetics BusinessBenzinga • 08/03/21
Bausch Health shares slide 6% premarket after surprise loss, says will seek IPO of Solta Medical businessMarket Watch • 08/03/21
Bausch Health Announces Plans To Pursue An Initial Public Offering Of Solta MedicalPRNewsWire • 08/03/21